技术与痴呆症 会议前会议
Josh King-Robson1, Eyal Soreq2,3,4, Molly R E Cartlidge1
1Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 23, 2025
概括
数字睡眠生物标志物在早期发现阿尔茨海默病病理学方面表现有前途. 一个使用床下传感器的新型模型识别了具有显著tau病理的个体,可与血液测试相比较.
科学领域:
- 神经学 神经学
- 生物标志物发现发现
- 老年学是指老年学的学科.
背景情况:
- 睡眠和昼夜干扰与痴呆症风险增加有关.
- 数字睡眠生物标志物为远程查初始痴呆症提供了一种低负担的方法.
- 这项研究探讨了使用Withings睡眠分析仪 (WSA) 来检测与阿尔茨海默病相关的生物标志物.
研究的目的:
- 评估使用数字睡眠生物标志物用于痴呆症查的可行性.
- 为了确定基于WSA的数字睡眠生物标志物对阿尔茨海默病理学的预测价值.
- 为了比较睡眠生物标志物的表现与化的 (pTau) 217.7.
主要方法:
- 洞察46研究的参与者接受了连续评估,包括粉样蛋白和蛋白PET扫描.
- 威廷斯睡眠分析仪 (WSA) 收集了连续睡眠,昼夜和生理数据.
- 使用"一次排除"的交叉验证方法来开发PET状态的预测模型.
主要成果:
- 总共有63,720个夜晚的睡眠数据从161名参与者收集了WSA和Tau PET数据.
- 一个训练有素的模型识别了患有Braak3+ tau病理的个体,AUROC为0.75.
- 该模型的性能与血pTau217可比,但对于早期的病理阶段效果较差.
结论:
- 在老年人群中,通过像WSA这样的设备进行远程睡眠和昼夜监测是可行的.
- 一个数字睡眠生物标志物模型显示了识别显著tau病理的潜力,类似于血pTau217.
- 这项研究提供了使用数字睡眠生物标志物来识别临床阿尔茨海默病高风险个体的概念证明.
相关概念视频
01:30Dementia
482
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
482
01:22Alzheimer's Disease: Treatment
744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
01:15Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K